<?xml version='1.0'?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:georss="http://www.georss.org/georss" xmlns:atom="http://www.w3.org/2005/Atom" >
<channel>
	<title><![CDATA[BOL: Related items]]></title>
	<link>https://bioinformaticsonline.com/related/22352?offset=1130</link>
	<atom:link href="https://bioinformaticsonline.com/related/22352?offset=1130" rel="self" type="application/rss+xml" />
	<description><![CDATA[]]></description>
	
	
<item>
  <guid isPermaLink='true'>https://bioinformaticsonline.com/researchlabs/view/34929/shendurelab</guid>
  <pubDate>Thu, 28 Dec 2017 09:57:50 -0600</pubDate>
  <link></link>
  <title><![CDATA[ShendureLab]]></title>
  <description><![CDATA[
<p>The mission of our lab is to develop and apply new technologies and methods for genetics, genomics and molecular biology. Most of our work exploits next-generation DNA sequencing which is effectively emerging as a broadly enabling microscope for the measurement of biological phenomena. Our ongoing work generally falls into six areas. These are listed below as links to representative publications in each area.</p>

<p>Developing New Molecular Methods</p>

<p>Genomic Approaches to Developmental Biology</p>

<p>Massively Parallel Functional Genomics</p>

<p>Translating Genomics to the Clinic</p>

<p>Genetic Basis of Human Disease</p>

<p>Genome Sequencing Technologies</p>

<p>http://krishna.gs.washington.edu/index.html<br />http://www.gs.washington.edu/faculty/shendure.htm</p>
]]></description>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/37257/asar-advanced-metagenomic-sequence-analysis-in-r</guid>
	<pubDate>Mon, 09 Jul 2018 05:20:50 -0500</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/37257/asar-advanced-metagenomic-sequence-analysis-in-r</link>
	<title><![CDATA[ASAR: Advanced metagenomic Sequence Analysis in R]]></title>
	<description><![CDATA[<p><span>An interactive data analysis tool for selection, aggregation and visualization of metagenomic data is presented. Functional analysis with a SEED hierarchy and pathway diagram based on KEGG orthology based upon MG-RAST annotation results is available.</span></p>
<p><span><span>To read the manual, please click the link&nbsp;</span><a href="https://askarbek-orakov.github.io/ASAR/">https://askarbek-orakov.github.io/ASAR/</a></span></p><p>Address of the bookmark: <a href="https://github.com/Askarbek-orakov/ASAR" rel="nofollow">https://github.com/Askarbek-orakov/ASAR</a></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/40955/the-global-alliance-for-genomics-and-health-ga4gh</guid>
	<pubDate>Sat, 08 Feb 2020 07:37:31 -0600</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/40955/the-global-alliance-for-genomics-and-health-ga4gh</link>
	<title><![CDATA[The Global Alliance for Genomics and Health (GA4GH)]]></title>
	<description><![CDATA[<p>The Global Alliance for Genomics and Health (GA4GH) is a policy-framing and technical standards-setting organization, seeking to enable responsible genomic data sharing within a <a href="https://www.ga4gh.org/genomic-data-toolkit/regulatory-ethics-toolkit/framework-for-responsible-sharing-of-genomic-and-health-related-data/">human rights framework</a>.</p>
<p>GA4GH core funders and sponsors enable our work and allow us to convene the international genomic data sharing community.</p>
<p>https://www.ga4gh.org/</p><p>Address of the bookmark: <a href="https://www.ga4gh.org/" rel="nofollow">https://www.ga4gh.org/</a></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/news/view/12883/breaking-chromosomes-to-study-cancer</guid>
	<pubDate>Fri, 18 Jul 2014 05:42:09 -0500</pubDate>
	<link>https://bioinformaticsonline.com/news/view/12883/breaking-chromosomes-to-study-cancer</link>
	<title><![CDATA[Breaking chromosomes to study cancer !!!]]></title>
	<description><![CDATA[<p>Chromosomes are present in every cell of our body and they contain the information the body needs to develop and function properly. This information is carried in genes that are arranged along the chromosomes. There are usually 46 chromosomes in every cell. These chromosomes come in pairs, one from our mother and one from our father. The chromosomes can be sorted into 23 pairs by looking at them down a microscope.</p><p>Most people who have a balanced translocation have the right amount of chromosome material but it has been rearranged in some way. This may happen if two chromosomes swap pieces (a reciprocal translocation). In other cases two whole chromosomes may become stuck together (a Robertsonian translocation). This page describes what happens when someone has a reciprocal translocation. <br /><br />Reciprocal chromosomal translocations occur following double-strand breaks (DSBs) in DNA when a section of one chromosome is exchanged with that of another, non-homologous chromosome. These exchanges may produce a dysfunctional fusion gene that disrupts cell growth and survival pathways, such as the translocations seen in leukemia and childhood sarcomas. <br /><br />Chromosomal translocations have been well studied in cancer cell lines which are associated with two types of cancer, acute myeloid leukemia and Ewing's sarcoma, but determining how they contribute to cancer development is complicated by additional mutations and altered gene expression profiles in these cultured cells. Now, Juan Carlos Ramirez, head of the Viral Vector Facility at the Fundacion Centro Nacional de Investigaciones Cardiovasculares (CNIC) and his colleagues Raul Torres at CNIC and Sandra Rodriguez-Peralez at the Spanish National Cancer Center (CNIO) in Madrid, Spain have used a new genome editing tool, CRISPR-Cas9, to induce chromosomal translocations for the first time in a human cell line and in primary cells. The study's authors conclude by stating that the use of this technology will allow for the clarification of how and why chromosomal translocation occurs, which without doubt will allow new anti-cancer therapeutic strategies to be tackled.</p><p>Using RNA-Guided Endonuclease (RGEN) technology or CRISPR/Cas9 genome engineering technology, CNIO and CNIC researchers have shown that it is possible to obtain such chromosomal translocations. The CRISPR-Cas9 system is extremely simple to introduce a cut at the desired locus, easier to design, and cheaper than many other systems. Using the CRISPR-Cas9 system, Ramirez and his colleagues reproduced the translocations observed in Ewing&rsquo;s Sarcoma (ES) and Acute Myeloid Leukemia (AML) patient cell lines in HEK293 cells and also generated the ES translocation in human mesenchymal stem cells and the AML translocation in umbilical cord blood cells.</p><p>By focusing on chromosomal translocation without the confounding characteristics of established cell lines, these new cells lines should help answer the fundamental question of what causes a cell to become cancerous. Ramirez and his team now look forward to modeling other chromosome translocations in a variety of cell types.</p><p>Reference:</p><p>http://en.wikipedia.org/wiki/Chromosomal_translocation</p><p>http://www.nature.com/ncomms/2014/140603/ncomms4964/abs/ncomms4964.html<br /><br /></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/news/view/42470/the-new-corona-variant-has-23-mutations-in-all-which-is-unusually-huge</guid>
	<pubDate>Wed, 23 Dec 2020 03:50:50 -0600</pubDate>
	<link>https://bioinformaticsonline.com/news/view/42470/the-new-corona-variant-has-23-mutations-in-all-which-is-unusually-huge</link>
	<title><![CDATA[The new corona variant has 23 mutations in all, which is unusually huge !]]></title>
	<description><![CDATA[<p>The new SARS-CoV-2 version, B.1.1.7, which was first seen in the third week of September in Kent and Greater London, has since spread to other locations in the UK. According to the COVID-19 Genomics UK Consortium (COG-UK Consortium) that analysed the genome data of the virus and identified the variant, the new variant has been spreading "rapidly" over the last four weeks and has now been detected in other locations in the UK, suggesting further spread of the variant in the region.</p><p><span>According to a<span>&nbsp;</span></span><a href="https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563"><strong><span>preliminary report</span></strong></a><span><span>&nbsp;</span>posted on December 19 by the COG-UK Consortium scientists, as of December 15, 1,623 variant genomes have been sequenced. In a<span>&nbsp;</span></span><a href="https://twitter.com/TheCGPS/status/1340749351803629569"><strong><span>December 21 tweet</span></strong></a><span>, COG-UK Consortium said that it added 2,963 more genome sequences of SARS-CoV-2, of which 942 (32%) belong to the new variant. The Consortium<span>&nbsp;</span></span><a href="https://twitter.com/CovidGenomicsUK/status/1341073233420955654"><strong><span>intends to sequence</span></strong></a><span><span>&nbsp;</span>20,000 more SARS-CoV-2 genomes in the next two weeks to further ascertain the spread of the variant.</span></p><p><span>There is no clear proof, at least not yet, that it does cause severe pandemic. But there is a justification for seriously taking the possibility. Another coronavirus lineage in South Africa has acquired one specific mutation that is also present in B.1.1.7. This variant is increasingly spreading across South Africa's coastal regions. And doctors have observed in preliminary research that individuals infected with this variant bear a higher viral load-a higher concentration of the virus in their upper respiratory tract. In many viral diseases, this is associated with more severe symptoms.</span></p><p>&nbsp;</p>]]></description>
	<dc:creator>Shruti Paniwala</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/43362/machine-learning-for-genomics</guid>
	<pubDate>Thu, 09 Sep 2021 11:26:32 -0500</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/43362/machine-learning-for-genomics</link>
	<title><![CDATA[Machine Learning for Genomics]]></title>
	<description><![CDATA[<h3>Module 1: Statistics for genomics (2-8 August 2021)</h3>
<ul>
<li>A simple intro to statistical distributions</li>
<li>hypothesis testing</li>
<li>linear models.</li>
</ul>
<p>reading:&nbsp;<a href="http://compgenomr.github.io/book/stats.html">http://compgenomr.github.io/book/stats.html</a></p>
<p>slides:&nbsp;<a href="https://github.com/BIMSBbioinfo/compgen2021/tree/main/week1/compgen2021_stats.pdf">https://github.com/BIMSBbioinfo/compgen2021/tree/main/week1/compgen2021_stats.pdf</a></p>
<p>exercises+code:&nbsp;<a href="https://github.com/BIMSBbioinfo/compgen2021/tree/main/week1/">https://github.com/BIMSBbioinfo/compgen2021/tree/main/week1/</a></p>
<h3><a href="https://github.com/BIMSBbioinfo/compgen2021#module-2-unsupervised-learning-for-genomics-9-15-august-2021"></a>Module 2: Unsupervised learning for genomics (9-15 August 2021)</h3>
<ul>
<li>Understanding basic intuition behind machine learning approaches.</li>
<li>Using unsupervised learning to cluster and visualise data points</li>
<li>Dimension reduction techniques for visualisation and as input to clustering methods</li>
</ul>
<p>reading:&nbsp;<a href="http://compgenomr.github.io/book/unsupervisedLearning.html">http://compgenomr.github.io/book/unsupervisedLearning.html</a></p>
<p>slides:&nbsp;<a href="https://github.com/BIMSBbioinfo/compgen2021/tree/main/week2/compgen2021_unsupervisedLearning.pdf">https://github.com/BIMSBbioinfo/compgen2021/tree/main/week2/compgen2021_unsupervisedLearning.pdf</a></p>
<p>exercises+code:&nbsp;<a href="https://github.com/BIMSBbioinfo/compgen2021/tree/main/week2/">https://github.com/BIMSBbioinfo/compgen2021/tree/main/week2/</a></p>
<h3><a href="https://github.com/BIMSBbioinfo/compgen2021#module-3-supervised-learning-for-genomics-16-22-august-2021"></a>Module 3: Supervised learning for genomics (16-22 August 2021)</h3>
<ul>
<li>Understanding and using supervised learning methods for predictive purposes</li>
<li>How to measure prediction performance</li>
<li>Understand and use cross-validation and related concepts</li>
</ul>
<p>reading:&nbsp;<a href="http://compgenomr.github.io/book/supervisedLearning.html">http://compgenomr.github.io/book/supervisedLearning.html</a></p>
<p>slides:&nbsp;<a href="https://github.com/BIMSBbioinfo/compgen2021/tree/main/week3/compgen2021_supervisedLearning.pdf">https://github.com/BIMSBbioinfo/compgen2021/tree/main/week3/compgen2021_supervisedLearning.pdf</a></p>
<p>exercises+code:&nbsp;<a href="https://github.com/BIMSBbioinfo/compgen2021/tree/main/week3/">https://github.com/BIMSBbioinfo/compgen2021/tree/main/week3/</a></p>
<p>https://github.com/BIMSBbioinfo/compgen2021</p><p>Address of the bookmark: <a href="https://github.com/BIMSBbioinfo/compgen2021" rel="nofollow">https://github.com/BIMSBbioinfo/compgen2021</a></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>

<item>
  <guid isPermaLink='true'>https://bioinformaticsonline.com/opportunity/view/44412/scientist-positions-csir-institute-of-genomics-integrative-biology-igib</guid>
  <pubDate>Sat, 02 Dec 2023 00:51:08 -0600</pubDate>
  <link></link>
  <title><![CDATA[Scientist positions @ CSIR-Institute of Genomics &amp; Integrative Biology (IGIB)]]></title>
  <description><![CDATA[
<p>CSIR-Institute of Genomics &amp; Integrative Biology (IGIB) is a premier Institute of Council of Scientific<br />and Industrial Research (CSIR), engaged in research of national importance in the areas of genomics,<br />molecular medicine, bioinformatics and proteomics. For more details, kindly refer to website<br />https://igib.res.in.<br />The Institute is looking for dynamic and creative Indian researchers having excellent academic record<br />and interested in Product Development / Technology Innovation / Applied Technology / Translational<br />Research in the above broad areas. The eligible candidates may apply for the following positions<br />through the CSIR-IGIB website.</p>

<p>More at https://www.igib.res.in/bdmg/ScientistRecruitmentAdvt2023.pdf</p>
]]></description>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/blog/view/44713/understanding-rna-seq-normalization-methods-tpm-vs-fpkm-vs-cpm</guid>
	<pubDate>Wed, 11 Dec 2024 00:59:15 -0600</pubDate>
	<link>https://bioinformaticsonline.com/blog/view/44713/understanding-rna-seq-normalization-methods-tpm-vs-fpkm-vs-cpm</link>
	<title><![CDATA[Understanding RNA-Seq Normalization Methods: TPM vs. FPKM vs. CPM]]></title>
	<description><![CDATA[<p>RNA sequencing (RNA-Seq) is a powerful technology used to study transcriptomes, providing insights into gene expression levels. However, raw RNA-Seq data requires normalization to account for sequencing depth and gene length, enabling accurate comparisons between genes and samples. Among the most widely used normalization methods are TPM (Transcripts Per Million), FPKM (Fragments Per Kilobase Million), and CPM (Counts Per Million). Each method has its unique principles and applications, which we&rsquo;ll explore in this blog.</p><h2>Why Normalize RNA-Seq Data?</h2><p>Normalization is a crucial step in RNA-Seq analysis for the following reasons:</p><ul>
<li>
<p><strong>Sequencing depth:</strong> Different RNA-Seq experiments produce varying numbers of reads, making direct comparisons between samples misleading.</p>
</li>
<li>
<p><strong>Gene length:</strong> Longer genes inherently generate more reads, irrespective of their actual expression level.</p>
</li>
<li>
<p><strong>Bias reduction:</strong> Normalization mitigates technical biases, enabling meaningful biological interpretation.</p>
</li>
</ul><h2>TPM (Transcripts Per Million)</h2><p>TPM measures the proportion of reads mapped to a transcript, normalized by transcript length and sequencing depth. It is calculated as:</p><h3>Key Features:</h3><ol>
<li>
<p><strong>Proportionality:</strong> TPM values sum to 1,000,000 across all transcripts in a sample, making it easier to compare between samples.</p>
</li>
<li>
<p><strong>Intuitive interpretation:</strong> TPM values directly represent the abundance of transcripts in a sample.</p>
</li>
<li>
<p><strong>Preferred for comparisons:</strong> TPM facilitates between-sample comparisons better than FPKM.</p>
</li>
</ol><h2>FPKM (Fragments Per Kilobase Million)</h2><p>FPKM normalizes read counts by transcript length and sequencing depth, but without enforcing proportionality like TPM. It is defined as:</p><h3>Key Features:</h3><ol>
<li>
<p><strong>Historical significance:</strong> FPKM was one of the first normalization methods used for RNA-Seq.</p>
</li>
<li>
<p><strong>Single-end vs. paired-end:</strong> In paired-end sequencing, FPKM becomes RPKM (Reads Per Kilobase Million).</p>
</li>
<li>
<p><strong>Limited utility:</strong> FPKM values are not as robust as TPM for cross-sample comparisons due to lack of proportionality.</p>
</li>
</ol><h2>CPM (Counts Per Million)</h2><p>CPM normalizes raw read counts by sequencing depth, without considering gene length. It is expressed as:</p><h3>Key Features:</h3><ol>
<li>
<p><strong>Simplicity:</strong> CPM is straightforward and computationally less intensive.</p>
</li>
<li>
<p><strong>Application:</strong> Suitable for non-length-dependent analyses, such as comparing total expression levels or differential expression analysis.</p>
</li>
<li>
<p><strong>Gene length agnostic:</strong> CPM does not correct for gene length, making it less ideal for measuring expression levels.</p>
</li>
</ol><h2>When to Use Each Method</h2><ul>
<li>
<p><strong>TPM:</strong> Best for comparing expression levels between samples, especially when transcript length and sequencing depth vary.</p>
</li>
<li>
<p><strong>FPKM:</strong> Useful for historical consistency but generally replaced by TPM.</p>
</li>
<li>
<p><strong>CPM:</strong> Ideal for differential expression analysis when gene length normalization is unnecessary.</p>
</li>
</ul><h2>Conclusion</h2><p>Choosing the right normalization method depends on the specific objectives of your RNA-Seq analysis. TPM&rsquo;s proportionality and robustness make it the preferred choice for most applications, while CPM serves well for differential expression studies. Although FPKM paved the way for RNA-Seq normalization, it has largely been supplanted by TPM in modern workflows. Understanding these methods and their nuances ensures accurate and meaningful interpretations of RNA-Seq data.</p><h3>References:</h3><ol>
<li>
<p>Li, B., &amp; Dewey, C. N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. <em>BMC Bioinformatics.</em></p>
</li>
<li>
<p>Trapnell, C., et al. (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. <em>Nature Biotechnology.</em></p>
</li>
<li>
<p>Law, C. W., et al. (2014). voom: precision weights unlock linear model analysis tools for RNA-seq read counts. <em>Genome Biology.</em></p>
</li>
</ol>]]></description>
	<dc:creator>Neel</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/3885/precision-medicine</guid>
	<pubDate>Sat, 24 Aug 2013 15:47:03 -0500</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/3885/precision-medicine</link>
	<title><![CDATA[Precision Medicine]]></title>
	<description><![CDATA[<p>Coupling established clinical&ndash;pathological indexes with state-of-the-art molecular profiling to create diagnostic, prognostic, and therapeutic strategies precisely tailored to each patient's requirements &mdash; hence the term &ldquo;Precision medicine&rdquo;&nbsp;</p>
<p>Source:<a href="http://www.nejm.org/doi/full/10.1056/NEJMp1114866">http://www.nejm.org/doi/full/10.1056/NEJMp1114866</a></p>
<p><strong>Another video on precision medicine</strong>:</p>
<p><a href="http://www.youtube.com/watch?v=Pi8W0yOXnzE">http://www.youtube.com/watch?v=Pi8W0yOXnzE</a></p>
<p>Precision Medicine basically intergrates bioinformatics, genomics , genetics, molecular biology and nanotechnology to deliver precise cure/diagnotics to a specific patient.</p>
<p>Examples:</p>
<ul>
<li><span>The drug imatinib (Gleevec) designed to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenous leukemia.</span></li>
<li><span>The breast cancer drug trastuzumab (Herceptin) works only for women whose tumors have a particular genetic profile called HER-2 positive.</span></li>
</ul>
<p><span>E.g. source :</span></p>
<p><span><a href="http://www.bionews-tx.com/news/2013/08/15/how-the-impact-of-cancer-genomics-on-precision-medicine-is-revolutionizing-cancer-treatment/">http://www.bionews-tx.com/news/2013/08/15/how-the-impact-of-cancer-genomics-on-precision-medicine-is-revolutionizing-cancer-treatment/</a></span></p><p>Address of the bookmark: <a href="http://www.cbsnews.com/video/watch/?id=50149783n" rel="nofollow">http://www.cbsnews.com/video/watch/?id=50149783n</a></p>]]></description>
	<dc:creator>Rahul Agarwal</dc:creator>
</item>
<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/bookmarks/view/34485/phyloxml-xml-for-evolutionary-biology-and-comparative-genomics</guid>
	<pubDate>Wed, 29 Nov 2017 10:04:48 -0600</pubDate>
	<link>https://bioinformaticsonline.com/bookmarks/view/34485/phyloxml-xml-for-evolutionary-biology-and-comparative-genomics</link>
	<title><![CDATA[phyloXML:  XML for evolutionary biology and comparative genomics]]></title>
	<description><![CDATA[<p><a href="http://www.biomedcentral.com/1471-2105/10/356/">phyloXML</a><span>&nbsp;(</span><a href="http://www.phyloxml.org/examples_syntax/phyloxml_syntax_example_1.html">example</a><span>) is an&nbsp;</span><a href="http://en.wikipedia.org/wiki/XML">XML</a><span>&nbsp;language designed to describe phylogenetic trees (or networks) and associated data. PhyloXML provides elements for commonly used features, such as taxonomic information, gene names and identifiers, branch lengths, support values, and gene duplication and speciation events. Using these standardized elements allows interoperability between various applications and databases. Furthermore, both due to extensible nature of XML itself and the provision of &lt;property&gt; elements by phyloXML, extensibility as well as domain specific applications are ensured. The structure of phyloXML is described by&nbsp;</span><a href="http://en.wikipedia.org/wiki/XML_Schema_%28W3C%29">XML Schema Definition (XSD)</a><span>&nbsp;language.</span></p><p>Address of the bookmark: <a href="http://www.phyloxml.org/" rel="nofollow">http://www.phyloxml.org/</a></p>]]></description>
	<dc:creator>Jit</dc:creator>
</item>

</channel>
</rss>